Researchers Discover That a Blood Thinner Significantly Reduces the Risk of Death After Non-Cardiac Surgery
First randomized controlled trial to evaluate a treatment for MINS
Researchers in Hamilton have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery.
Every year, approximately eight million people world-wide develop a condition called myocardial injury after non-cardiac surgery (MINS), which refers to damage incurred to the tissue of the heart in response to the stress of surgery on the body. The condition affects patients undergoing major procedures such as a hip or knee replacement, bowel resection, or abdominal aortic aneurysm repair, and can lead to severe complications including heart attack, stroke, blood clots, amputations, and death.
Click here to read more.
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
Surgical Approaches to Skull Base
April 26-28, 2018; St. Louis, MO
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
Goodman Oral Board Preparation Course
May 2-4, 2018; Phoenix
2018 Advanced Endoscopic Skull Base and Pituitary Surgery
June 1-2, 2018; New York
Be the first to reply using the above form.